Organogenesis Holdings Inc. Class A Common Stock (ORGO)

Price$2.42

Value ScoreB

Growth ScoreB

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-61.21%

Price vs S&P 500 (4W)2.12%

VGM Score58.86

Market Capitalization$311.39M

P/E Ratio (Annual)8.41x

All Metrics

P/CF (Annual)28.67x

Book Value / Share (Quarterly)$2.96

P/TBV (Annual)1.55x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)7.76%

Cash Flow / Share (Quarterly)$0.13

Price vs S&P 500 (YTD)-61.44%

Gross Margin (TTM)72.88%

Net Profit Margin (TTM)0.53%

EPS (TTM)$-0.02

10-Day Avg Trading Volume1.00M

EPS Excl Extra (TTM)$-0.02

Revenue Growth (5Y)10.77%

EPS (Annual)$0.28

ROI (Annual)8.12%

Gross Margin (Annual)75.62%

Net Profit Margin (5Y Avg)6.32%

Cash / Share (Quarterly)$0.71

P/E Basic Excl Extra (TTM)114.52x

Revenue Growth QoQ (YoY)-57.06%

EPS Growth (5Y)12.99%

P/E Normalized (Annual)8.41x

ROA (Last FY)6.19%

Revenue Growth TTM (YoY)12.19%

EBITD / Share (TTM)$0.14

ROE (5Y Avg)11.11%

Operating Margin (TTM)0.50%

Cash Flow / Share (Annual)$-0.19

P/B Ratio0.82x

P/B Ratio (Quarterly)0.80x

Net Income / Employee (Annual)$43,400

EV / Revenue (TTM)0.45x

Net Interest Coverage (TTM)-0.82x

ROA (TTM)0.52%

EPS Growth QoQ (YoY)423.65%

EV / EBITDA (TTM)12.55x

EPS Incl Extra (Annual)$0.28

Current Ratio (Annual)3.62x

Quick Ratio (Quarterly)2.78x

3-Month Avg Trading Volume1.25M

52-Week Price Return-15.97%

EV / Free Cash Flow (Annual)83.08x

P/E Incl Extra (TTM)114.52x

Revenue / Employee (TTM)$602,700

Tangible BV / Share (Quarterly)$2.94

P/S Ratio (Annual)0.55x

Asset Turnover (Annual)0.94x

52-Week High$7.08

Operating Margin (5Y Avg)6.13%

EPS Excl Extra (Annual)$0.28

CapEx CAGR (5Y)-4.36%

Tangible BV CAGR (5Y)29.75%

26-Week Price Return-53.28%

Quick Ratio (Annual)3.14x

13-Week Price Return-16.55%

Total Debt / Equity (Annual)0.05x

Current Ratio (Quarterly)3.53x

Enterprise Value$232.88M

Revenue / Share Growth (5Y)7.36%

Asset Turnover (TTM)0.99x

Book Value / Share Growth (5Y)24.47%

Revenue / Employee (Annual)$660,600

Inventory Turnover (Annual)4.92x

Pretax Margin (Annual)8.33%

Cash / Share (Annual)$0.74

3-Month Return Std Dev58.84%

Gross Margin (5Y Avg)75.87%

Net Income / Employee (TTM)$3,200

EBITDA CAGR (5Y)12.46%

EBITDA Interim CAGR (5Y)24.16%

ROE (Last FY)8.53%

Net Interest Coverage (Annual)-6.05x

EPS Basic Excl Extra (Annual)$0.28

P/FCF (TTM)5.81x

Receivables Turnover (TTM)4.67x

EV / Free Cash Flow (TTM)13.63x

Total Debt / Equity (Quarterly)0.03x

EPS Incl Extra (TTM)$-0.02

Receivables Turnover (Annual)3.45x

ROI (TTM)0.68%

P/S Ratio (TTM)0.60x

Pretax Margin (5Y Avg)5.66%

Revenue / Share (Annual)$4.33

Tangible BV / Share (Annual)$3.35

Forward P/E21.65x

Price vs S&P 500 (52W)-40.34%

P/E Ratio (TTM)114.52x

EPS Growth TTM (YoY)3600.00%

Year-to-Date Return-53.28%

5-Day Price Return2.54%

EPS Normalized (Annual)$0.28

ROA (5Y Avg)6.46%

Net Profit Margin (Annual)6.56%

Month-to-Date Return-5.84%

Cash Flow / Share (TTM)$0.20

EBITD / Share (Annual)$0.46

EPS Growth (3Y)34.40%

Operating Margin (Annual)7.92%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)10.13x

ROI (5Y Avg)8.89%

P/E Excl Extra (TTM)114.52x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.02

P/TBV (Quarterly)0.81x

P/B Ratio (Annual)1.51x

Inventory Turnover (TTM)4.83x

Pretax Margin (TTM)0.83%

Book Value / Share (Annual)$3.42

Price vs S&P 500 (13W)-24.81%

Net Margin Growth (5Y)5.25%

Beta1.36x

P/FCF (Annual)74.57x

Revenue / Share (TTM)$4.03

ROE (TTM)0.70%

52-Week Low$2.04

vGradeB

gGradeB

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.41est. -0.32

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.25

4.29

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ORGOOrganogenesis Holdings Inc. Class A Common Stock	B	B	C	$2.42
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Organogenesis is a regenerative medicine company specializing in advanced wound care, surgical, and sports medicine markets. The company develops and commercializes bioengineered tissue products designed to accelerate healing and improve surgical outcomes. Its portfolio includes solutions for chronic wound management, acute surgical applications, and soft tissue repair across hospital and outpatient settings.